Pharmacogenomics and personality: Role of CYP2D6 and implications for psychopathology

Pharmacogenomics in Psychiatry

Volumn 25, Issue , 2010, Pages 30-45

  Peñas LLedó, Eva M ^a   Dorado, Pedro ^a,b   LLerena, Adrián ^a,b  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897857221     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000317297     Document Type: Chapter

References (80)

1. Dorado P, Berecz R, Peñas-Lledó EM, Cáceres MC, Llerena A: Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Curr Drug Targets 2006; 7: 671-680.
2. Dorado P, Peñas-Lledó EM, Llerena A: CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007; 8: 1597-1608.
3. Llerena A, Dorado P, Peñas-Lledó EM: Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009; 10: 17-28.
4. Kawashima H, Sequeira DJ, Nelson DR, Strobel HW: Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18 * catalyzing imipramine N-demethylation. J Biol Chem 1996; 271: 28176-28180.
5. Wyss A, Gustafsson JA, Warner M: Cytochromes P450 of the 2D subfamily in rat brain. Mol Pharmacol 1995; 47: 1148-1155.
6. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249: 838-843.
7. Tyndale RF, Li Y, Li NY, Messina E, Miksys S, Sellers EM: Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos 1999; 27: 924-930.
8. Norris PJ, Hardwick JP, Emson PC: Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J Comp Neurol 1996; 366: 244-258.
9. Riedl AG, Watts PM, Edwards RJ, Schulz-Utermoehl T, Boobis AR, Jenner P, Marsden CD: Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Res 1999; 822: 175-191.
10. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, Baumann P: Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000; 855:235-243.
11. Miksys SL, Tyndale RF: Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci 2002; 27: 406-415.
12. Fonne-Pfister R, Bargetzi MJ, Meyer UA: MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987; 148: 1144-1150.
13. McFadyen MC, Melvin WT, Murray GI: Cytochrome P450 in normal human brain and brain tumours. Biochem Soc Trans 1997; 25:S577.
14. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, Wolf CR: Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997; 27: 111-125.
15. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M: Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11:237-245.
16. Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P-4502D6. Acta Psychiatr Scand 1993; 87: 23-28.
17. Bromek E, Haduch A, Daniel WA: The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study. Eur J Pharmacol 2010; 626: 171-178.
18. Yu AM, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ:Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 2003; 305: 315-322.
19. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173-181.
20. Yu AM, Idle JR, Gonzalez FJ: Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004; 36:243-277.
21. Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R, Roots I, Brockmöller J:Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15: 579-587.
22. Ozdemir V, Gunes A, Dahl ML, Scordo MG, Williams-Jones B, Someya T: Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness? Pharmacogenomics 2006; 7: 1199-1210.
23. Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, Widén J, Svensson JO, Albers LJ, Kennedy JL, Endrenyi L, Kalow W: CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17: 339-347.
24. Frankle WG, Lombardo I, New AS, Goodman M, Talbot PS, Huang Y, Hwang DR, Slifstein M, Curry S, Abi-Dargham A, Laruelle M, Siever LJ: Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [ 11 C]McN 5652. Am J Psychiatry 2005; 162:915-923.
25. Carli M, Baviera M, Invernizzi RW, Balducci C:Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 2006; 31: 757-767.
26. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, Hollenberg PF: The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 2008; 327: 538-545.
27. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y: Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001; 142: 3901-3908.
28. Kishimoto W, Hiroi T, Shiraishi M, Osada M, Imaoka S, Kominami S, Igarashi T, Funae Y: Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology 2004; 145: 699-705.
29. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D: Debrisoquine hydroxylation polymorphism and personality. Lancet 1989; 1: 555.
30. Llerena A, Cobaleda J, Benítez J: Debrisoquine hydroxylation phenotypes in healthy volunteers. Lancet 1989; 8651: 1398.
31. Ortet G, Torrubia R: Spanish language version of the Karolinska Scales of Personality (KSP): First data. VI Eur Conf Personality, Groningen, 1992.
32. Ortet G, Ibáñez M, Llerena A, Torrubia R: The underlying traits of the Karolinska Scales of Personality (KSP). Eur J Psychological Assess 2002; 18: 139-148.
33. Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V: CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007; 17: 989-993.
34. González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, Llerena A: Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008; 9:833-840.
35. Peñas-Lledó EM, Dorado P, Pacheco R, González I, Llerena A: Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009; 10: 1111-1120.
36. Kirchheiner J, Lang U, Stamm T, Sander T, Gallinat J: Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol 2006; 26: 440-442.
37. Suzuki E, Kitao Y, Ono Y, Iijima Y, Inada T: Cytochrome P450 2D6 polymorphism and character traits. Psychiatr Genet 2003; 13: 111-113.
38. Iwashima K, Yasui-Furukori N, Kaneda A, Saito M, Nakagami T, Sato Y, Kaneko S: No association between CYP2D6 polymorphisms and personality trait in Japanese. Br J Clin Pharmacol 2007; 64: 96-99.
39. Costa PT, McCrae RR: NEO personality Inventory professional manual. Odessa, Psychological Assessment Resources, 1992.
40. Salgado JF: The five factor model of personality and job performance in the European community. J Appl Psychol 1997; 82: 30-43.
41. Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Kumaraswamy N, Larmie ET: Relationship between type A and B personality and debrisoquine hydroxylation capacity. Br J Clin Pharmacol 2004; 57: 785-789.
42. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA: Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet 2004; 127: 90-93.
43. Mulder RT, Joyce PR, Sullivan PF, Bulik CM, Carter FA: The relationship among three models of personality psychopathology: DSM-III-R personality disorder, TCI scores and DSQ defences. Psychol Med 1999; 29: 943-951.
44. Lasagna L, Von Felsinger JM: The volunteer subject in research. Science 1954; 120: 359-361.
45. Pollin W, Perlin S: Psychiatric evaluation of 'normal control' volunteers. Am J Psychiatry 1958; 115: 129-133.
46. Halbreich U, Bakhai Y, Bacon KB, Goldstein S, Asnis GM, Endicott J, Lesser J: The normalcy of selfproclaimed 'normal volunteers'. Am J Psychiatry 1989; 146: 1052-1055.
47. Thaker GK, Moran M, Lahti A, Adami H, Tamminga C: Psychiatric morbidity in research volunteers. Arch Gen Psychiatry 1990; 47: 980.
48. Shtasel DL, Gur RE, Mozley PD, Richards J, Taleff MM, Heimberg C, Gallacher F, Gur RC: Volunteers for biomedical research: recruitment and screening of normal controls. Arch Gen Psychiatry 1991; 48:1022-1025.
49. Tishler CL, Apseloff G, Bartholomae S, Reiss NS, Rhodes AR, Singh A: Are normal healthy research volunteers psychologically healthy? A pilot investigation. Exp Clin Psychopharmacol 2007; 15: 539-545.
50. Schechter D, Lebovitch R: Normal controls are expensive to find: methods to improve cost-effectiveness of the screening evaluation. Psychiatry Res 2005; 136: 69-78.
51. Derogatis LR: Misuse of the Symptom Checklist 90. Arch Gen Psychiatry 1983; 40: 1152-1153.
52. Gustavsson JP, Asberg M, Schalling D: The healthy control subject in psychiatric research: impulsiveness and volunteer bias. Acta Psychiatr Scand 1997; 96: 325-328.
53. Almeida L, Kashdan TB, Nunes T, Coelho R, Albino-Teixeira A, Soares-da-Silva P: Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events. Eur J Clin Pharmacol 2008; 64: 575-582.
54. Cools R, Roberts AC, Robbins TW: Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci 2008; 12: 31-40.
55. Williams J, Dayan P: Dopamine, learning, and impulsivity:a biological account of attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15: 160-179.
56. Pattij T, Vanderschuren LJ: The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci 2008; 29: 192-199.
57. Russell VA: Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder - the spontaneously hypertensive rat. Neurosci Biobehav Rev 2003; 27: 671-682.
58. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA: Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 2003; 53: 352-359.
59. Abdolmaleky HM, Smith CL, Zhou JR, Thiagalingam S: Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol 2008; 448: 187-212.
60. Bachner-Melman R, Lerer E, Zohar AH, Kremer I, Elizur Y, Nemanov L, Golan M, Blank S, Gritsenko I, Ebstein RP: Anorexia nervosa, perfectionism, and dopamine D4 receptor (DRD4). Am J Med Genet B Neuropsychiatr Genet 2007; 144B:748-756.
61. Benjamin J, Osher Y, Lichtenberg P, Bachner-Melman R, Gritsenko I, Kotler M, Belmaker RH, Valsky V, Drendel M, Ebstein RP: An interaction between the catechol O-methyltransferase and serotonin transporter promoter region polymorphisms contributes to tridimensional personality questionnaire persistence scores in normal subjects. Neuropsychobiology 2000; 41: 48-53.
62. Schosser A, Fuchs K, Scharl T, Schloegelhofer M, Kindler J, Mossaheb N, Kaufmann RM, Leisch F, Kasper S, Sieghart W, Aschauer HN: Interaction between serotonin 5-HT2A receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians. World J Biol Psychiatry 2008; 1:1-8.
63. Anestis MD, Selby EA, Joiner TE: The role of urgency in maladaptive behaviors. Behav Res Ther 2007; 45: 3018-3029.
64. Shafran R, Cooper Z, Fairburn CG: Clinical perfectionism:a cognitive-behavioural analysis. Behav Res Ther 2002; 40: 773-791.
65. Stoeber J, Kersting M: Perfectionism and aptitude test performance: testes who strive for perfection achieve better test results. Pers Individ Dif 2007; 42:1093-1103.
66. Bailey SP, Davis JM, Ahlborn EN: Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993; 74: 3006-3012.
67. Flaa A, Ekeberg O, Kjeldsen SE, Rostrup M: Personality may influence reactivity to stress. Biopsychosoc Med 2007; 1: 5.
68. Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A: Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 2007; 7: 408-410.
69. Dahl AA, Løwert A, Asserson S, Bjarking L, Berglund J, Kristensen F, Norum D, Tønseth S, Bayer L, Mæhlum E: Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum Psychopharmacol 1998; 13: 509-511.
70. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, Roots I: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72:438-452.
71. Dawson E, Powell JF, Nothen MM, Crocq MA, Lanczik M, Korner J, Rietschel M, van Os J, Wright P, Gill M: An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr Genet 1994; 4: 215-218.
72. Daniels J, Williams J, Asherson P, McGuffin P, Owen M: No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Genet 1995; 60: 85-87.
73. Pirmohamed M, Wild MJ, Kitteringham NR, O'Brien K, Buchan IE, Back DJ, Park BK: Lack association between schizophrenia and the CYP2D6 gene polymorphisms. Am J Med Genet 1996; 67:236-237.
74. Jonsson EG, Dahl ML, Roh HK, Jerling M, Sedvall GC: Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia. Psychiatr Genet 1998; 8: 25-28.
75. Chen CH, Hung CC, Wei FC, Koong FJ: Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr Genet 2001; 11: 153-155.
76. Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Tiemeier H, Stricker BH: Association between the CYP2D6 * 4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics 2009; 10:541-547.
77. Josefsson A, Sydsjö G, Berg G, Dahl ML, Wadelius M, Nordin C: CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum. Nord J Psychiatry 2004; 58: 61-64.
78. Cools R: Role of dopamine in the motivational and cognitive control of behaviour. Neuroscientist 2008; 14: 381-395.
79. Bellgrove MA, Mattingley JB: Molecular genetics of attention. Ann N Y Acad Sci 2008; 1129: 200-212.
80. Matrenza C, Hughes JM, Kemp AH, Wesnes KA, Harrison BJ, Nathan PJ: Simultaneous depletion of serotonin and catecholamines impairs sustained attention in healthy female subjects without affecting learning and memory. J Psychopharmacol 2004; 18: 21-31.